Evaluation of safety and immunogenicity of feline vaccines with reduced volume.

Vaccine

Boehringer-Ingelheim Animal Health SCS France, R&D, 29 Avenue Tony Garnier, 69007 Lyon, France.

Published: February 2021

A non adjuvanted vaccine against feline herpesvirus, feline calicivirus, feline panleucopenia and feline leukemia has been formulated in reduced volume (0.5 ml) with the same antigen content as the conventional 1 ml presentation. This paper reports studies evaluating the safety and the immunogenicity of this reduced volume vaccine in comparison with the conventional volume vaccine. The safety of both vaccines was evaluated in a small sized laboratory trial. It was further tested in a randomized controlled field trial on a total of 398 cats. Immediate and delayed local and systemic adverse events were monitored after vaccination. The immunogenicity of each vaccine was also checked by serological antibody responses against the vaccines antigens during the laboratory trial. These studies showed that the 0.5 ml vaccine was well tolerated in cats, inducing less local events, while keeping the same immunogenicity as the corresponding 1 ml vaccine. Reducing the volume of the vaccine is a way to improve the convenience of administration and to help following vaccination guidelines with the aim of reducing the incidence of adverse events following vaccination.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2021.01.026DOI Listing

Publication Analysis

Top Keywords

reduced volume
12
volume vaccine
12
safety immunogenicity
8
laboratory trial
8
adverse events
8
vaccine
7
feline
5
volume
5
evaluation safety
4
immunogenicity
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!